UFMylation of SHBs increases protein stability by antagonizing ubiquitination and promotes virion production
- 1Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China
- 2Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China
Abstract
Post-translational modifications orchestrate virus–host interactions, yet their roles in the hepatitis B virus (HBV) life cycle remain incompletely defined. The small hepatitis B surface antigen (SHBs)—the most abundant HBV protein—drives immune evasion, pathogenesis, and virion/subviral particle (SVP) production. Here, we identify UFL1, the E3 ligase of UFMylation, as a host factor that modifies and stabilizes SHBs by antagonizing its ubiquitination to potentiate HBV output and SHBs-driven pro-oncogenic activities. Using affinity purification-mass spectrometry, we discovered UFL1 as a SHBs interactor and validated the interaction by co-immunoprecipitation, confocal co-localization, and GST pull-down assays. In vivo and in vitro UFMylation assays demonstrated that UFL1 catalyzes SHBs’ UFMylation. Site-directed mutagenesis mapped the modification to K122; the K122R mutant failed to undergo UFMylation. Cycloheximide chase and ubiquitination assays showed that UFMylation at K122 stabilizes SHBs by antagonizing TRIM21-mediated K48-linked polyubiquitination and proteasomal degradation. Functionally, UFL1 enhanced SHBs-driven hepatocellular carcinoma cell migration and endothelial tube formation, whereas UFL1 knockdown produced opposite effects. In HBV-producing cells, UFL1 increased intracellular and extracellular HBsAg and HBV virions, with no effects on HBV RNA, indicating post-translational control of HBsAg and virion/SVP production. These findings establish SHBs as, to our knowledge, the first HBV protein substrate of UFMylation and reveal a UFL1-SHBs axis that promotes SHBs stability, pathogenic functions, and HBV particle output. Targeting UFMylation or the UFL1-SHBs interface offers a host-directed strategy to reduce HBsAg and virion production and may inform therapeutic approaches for HBV infection and HBV-related liver disease.
IMPORTANCE: Chronic infection with hepatitis B virus (HBV) remains a major global health problem, in part because current treatments rarely reduce the viral surface protein that floods the blood and helps the virus persist. In this study, we asked how the most abundant viral surface protein—SHBs—is controlled inside cells. We discovered that UFL1 attaches a small “molecular tag” as UFM1 to this viral protein, and this tag protects the SHBs from the cell’s disposal system. As a result, the increased SHBs promotes behaviors linked to liver disease progression, and cells release more virion/SVPs. When we prevented this tagging event or changed a single amino acid on the SHBs so it could not be tagged, the protein became unstable and was degraded, and virus output dropped. Thus, to our knowledge, SHBs is the first identified HBV protein substrate of UFMylation, suggesting targeting the UFL1-SHBs interface may reduce HBsAg and virion production and inform HBV therapy.
Related
- RNF220 safeguards meiotic synapsis and male fertility by antagonizing SYCE1 ubiquitination.
- Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy
- Pre-harvest mechanical stress increases cannabinoid and terpene production in cannabis
- The SynMuvA lin-15A licenses natural transdifferentiation by antagonizing identity safeguarding mechanisms
- Palmatine Induces TNNT1 Ubiquitination and Degradation to Potentiate Ferroptosis Sensitivity in Hepatocellular Carcinoma
BibTeX
@article{wu2026ufmylation,
title = {{UFMylation of SHBs increases protein stability by antagonizing ubiquitination and promotes virion production}},
author = {Shuxiang Wu and Yilin Huang and Jing Xu and Jie Li and Xiaohuang Lin and Xinjian Lin and Xu Lin},
journal = {Journal of Virology},
year = {2026},
month = sep,
doi = {10.1128/jvi.01034-26},
url = {https://doi.org/10.1128/jvi.01034-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - UFMylation of SHBs increases protein stability by antagonizing ubiquitination and promotes virion production
AU - Shuxiang Wu
AU - Yilin Huang
AU - Jing Xu
AU - Jie Li
AU - Xiaohuang Lin
AU - Xinjian Lin
AU - Xu Lin
PY - 2026
DA - 2026/09/22
JO - Journal of Virology
DO - 10.1128/jvi.01034-26
UR - https://doi.org/10.1128/jvi.01034-26
AB - Post-translational modifications orchestrate virus–host interactions, yet their roles in the hepatitis B virus (HBV) life cycle remain incompletely defined. The small hepatitis B surface antigen (SHBs)—the most abundant HBV protein—drives immune evasion, pathogenesis, and virion/subviral particle (SVP) production. Here, we identify UFL1, the E3 ligase of UFMylation, as a host factor that modifies and stabilizes SHBs by antagonizing its ubiquitination to potentiate HBV output and SHBs-driven pro-oncogenic activities. Using affinity purification-mass spectrometry, we discovered UFL1 as a SHBs interactor and validated the interaction by co-immunoprecipitation, confocal co-localization, and GST pull-down assays. In vivo and in vitro UFMylation assays demonstrated that UFL1 catalyzes SHBs’ UFMylation. Site-directed mutagenesis mapped the modification to K122; the K122R mutant failed to undergo UFMylation. Cycloheximide chase and ubiquitination assays showed that UFMylation at K122 stabilizes SHBs by antagonizing TRIM21-mediated K48-linked polyubiquitination and proteasomal degradation. Functionally, UFL1 enhanced SHBs-driven hepatocellular carcinoma cell migration and endothelial tube formation, whereas UFL1 knockdown produced opposite effects. In HBV-producing cells, UFL1 increased intracellular and extracellular HBsAg and HBV virions, with no effects on HBV RNA, indicating post-translational control of HBsAg and virion/SVP production. These findings establish SHBs as, to our knowledge, the first HBV protein substrate of UFMylation and reveal a UFL1-SHBs axis that promotes SHBs stability, pathogenic functions, and HBV particle output. Targeting UFMylation or the UFL1-SHBs interface offers a host-directed strategy to reduce HBsAg and virion production and may inform therapeutic approaches for HBV infection and HBV-related liver disease. IMPORTANCE: Chronic infection with hepatitis B virus (HBV) remains a major global health problem, in part because current treatments rarely reduce the viral surface protein that floods the blood and helps the virus persist. In this study, we asked how the most abundant viral surface protein—SHBs—is controlled inside cells. We discovered that UFL1 attaches a small “molecular tag” as UFM1 to this viral protein, and this tag protects the SHBs from the cell’s disposal system. As a result, the increased SHBs promotes behaviors linked to liver disease progression, and cells release more virion/SVPs. When we prevented this tagging event or changed a single amino acid on the SHBs so it could not be tagged, the protein became unstable and was degraded, and virus output dropped. Thus, to our knowledge, SHBs is the first identified HBV protein substrate of UFMylation, suggesting targeting the UFL1-SHBs interface may reduce HBsAg and virion production and inform HBV therapy.
SN - 0022-538X
SN - 1098-5514
ER -